ENTITY
Johnson & Johnson’s Oncology Segment Thrives with Darzalex and Carvykti, Offsetting Stelara Decline
Johnson & Johnson, Darzalex, Carvykti, Stelara, Oncology, Multiple Myeloma, Pharmaceutical Sales
MeiraGTx’s Gene Therapy Shows Significant Improvements in Motor Function and Quality of Life in Parkinson’s Disease Trial
MeiraGTx, Gene Therapy, Parkinson’s Disease, AAV-GAD, Motor Function, Quality of Life, Clinical Trial, Phase 2 Trial, Neurodegenerative Disease, Dopamine Replacement, GABA Production
WuXi AppTec and WuXi Biologics Consider Asset Sales Amid BIOSECURE Act Scrutiny
WuXi AppTec, WuXi Biologics, BIOSECURE Act, asset sales, biotech industry, US-China relations
HIV Prevention: A Proven Solution Eludes Many Due to Systemic Barriers
HIV Prevention, PrEP (Pre-Exposure Prophylaxis), Health Equity, Marginalized Communities, Stigma, Access to Healthcare
Jazz Pharmaceuticals Advances Combination Therapy for Extensive-Stage Small Cell Lung Cancer
Jazz Pharmaceuticals, Zepzelca, lurbinectedin, atezolizumab, ES-SCLC, first-line maintenance therapy, small cell lung cancer, Phase 3 IMforte trial
Tolerance Bio Secures $17.2M Seed Funding to Develop Thymus-Targeted Cell Therapies
Tolerance Bio, cell therapy, thymus, immune-mediated diseases, seed funding, allogeneic iPSC-based therapy
MeiraGTx Announces Positive Phase 2 Data for AAV-GAD Gene Therapy in Parkinson’s Disease, Paving Way for Phase 3 Trial
MeiraGTx, AAV-GAD, Gene Therapy, Parkinson’s Disease, Phase 2 Trial, Phase 3 Trial, Neurodegenerative Disorders, Genetic Medicine
FDA Approves CMR Surgical’s Versius Robot for Cholecystectomies in Adults
CMR Surgical, Versius Surgical System, FDA Approval, Cholecystectomies, Robotic-Assisted Surgery
Pfizer and Triana Biomedicines Collaborate on Molecular Glue Discovery for Cancer and Other Diseases in $1.5 Billion Deal
Pfizer, Triana Biomedicines, molecular glue, cancer, oncology, drug discovery, biotechnology, pharmaceuticals
Forbion Secures Over €2 Billion in Largest Fundraising to Date, Supporting 30 Biotechs
Forbion, venture capital, life sciences, fundraising, biotechs, Forbion Growth Opportunities Fund III, Forbion Ventures Fund VII